Aimmune Therapeutics (AIMT)

November 9, 2016 6:40 AM EST
Get Alerts AIMT Hot Sheet
Price: $22.26 +1.09%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade AIMT Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Wedbush analyst, Liana Moussatos, reiterated her Outperform rating on Aimmune Therapeutics (NASDAQ: AIMT) after recent data reinforced her view that AR101 is the best in class for the peanut allergy.

The analyst believes that recently released results from competition reinforce her view that AR101 has best-in-class efficacy for peanut desensitization. This implies that shares of AIMT have been and are likely to continue to increase in value with important catalysts in 2017 when Phase 3 results are expected to be released.

After incorporating the additional $145 million in cash and 7.6 million shares from the recent Nestle Health Science collaboration, the analyst increased her cash runway projection into the Q4 2018.

No change to the price target of $42.

For an analyst ratings summary and ratings history on Aimmune Therapeutics click here. For more ratings news on Aimmune Therapeutics click here.

Shares of Aimmune Therapeutics closed at $20.64 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change

Related Entities

Liana Moussatos

Add Your Comment